Abstract
TPS5615 Background: The objective of chemotherapy in women with platinum resistant recurrent ovarian cancer is symptom palliation. Response rates or time to progression are used to assess “clinical benefit”, but fail to incorporate subjective benefit. There is international consensus that a valid measure of subjective symptom benefit is required. The aims of Stage 2 of this study are to assess the validity, reliability and statistical efficiency of a new patient-reported outcome measure, the Measure of Ovarian Symptoms and Treatment concerns (MOST, developed in Stage 1), relative to the best candidate scales of existing ovarian cancer specific quality of life measures (QLQ-C30/OV28, FACT-O/FOSI), develop criteria for defining subjective symptom benefit, determine how many women have subjective benefit with palliative chemotherapy and develop a prognostic model to better predict benefit, time to progression and survival in this heterogeneous group of patients. Methods: Prospective observational cohort stud...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
